Short-sighted move

Published
3

THE prime minister and cabinet’s populist decision to reject a fresh proposal from the health ministry to raise prices of 10 medicines under ‘hardship cases’ will not benefit any stakeholder: the government, producers or patients. Last month, the Shehbaz Sharif government refused to increase the price of 35 medicines under the hardship category; these represent cases where the production of a drug becomes economically unviable at its existing fixed retail price, which then leads to its shortage and disappearance from the market.

Over the last year, many medicines have fallen into this category due to runaway inflation, steep exchange rate depreciation, a sharp hike in the electricity tariff and transportation costs, etc. On top of that, global inflation has led to a significant spike in the cost of imported raw materials, forcing manufacturers to reduce or discontinue some essential products because of their unrealistically low retail prices, causing their shortage in the market. The void created by the unavailability of these essential medicines is encouraging an influx of spurious, and in some cases smuggled, products into the market at great expense to public health safety. With drugmakers having exhausted their raw material inventories, it is being feared that more drugs will vanish from the market unless the government allows a price increase to compensate the manufacturers for the hike in their production costs. As painful as the uptick in price will be for many, medicine shortages can be even more distressing as can be seen with Panadol, a commonplace drug used to treat aches and fever which is presently hard to find. People then end up paying much more than the medicine’s fixed price in order to get their hands on it. If the government wants to help the vulnerable segments of society, it should learn to regulate drug prices by encouraging market competition rather than through price administration. For a longer-term resolution, the health authorities could impose a levy on manufacturers’ turnover to fund provision of free medicines to the poor.

Published in Dawn, September 15th, 2022

Opinion

Editorial

Makkah pact clarity
Updated 22 Oct, 2026

Makkah pact clarity

Fresh aggression can kick off a firestorm that will be in no one’s control, hence it is best to abandon such reckless plans.
Common ground
Updated 22 Oct, 2026

Common ground

Regrettably, the two sides still fail to see the country’s economic, security, and governance crises as challenges that must be solved politically.
The treatment gap
22 Oct, 2026

The treatment gap

A BREAST cancer diagnosis no longer carries the bleak outlook it did a generation ago. Targeted medicines,...
Real FBR reform
21 Oct, 2026

Real FBR reform

REFORM of the FBR has always been easier to promise than to deliver. Since the late 1990s, governments have tried...
Missing lawmakers
Updated 21 Oct, 2026

Missing lawmakers

Some lawmakers have reportedly been in detention since before Oct 11.
Tackling rabies
21 Oct, 2026

Tackling rabies

RABIES is a deadly but preventable zoonotic disease. On Monday, two more victims succumbed to it in Sindh, taking ...